my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
BioXell is a biopharmaceutical company focused on the discovery and development of drugs that exploit novel mechanisms of action to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company was founded in 2002 as a spin-out from Roche. BioXell more
BioXell S.p.A. announced that, on 26 February 2010, which is the end of the additional acceptance period, Cosmo Pharmaceuticals S.p.A. holds 98.96 percent of the shares, respectively voting rights of BioXell S.p.A, Milano. Until the end of the additional acceptance period on 26 February 2010, 5,32 more
BioXell S.p.A. announced that, on 8 February 2010, which is the end of the offer period, Cosmo Pharmaceuticals S.p.A. holds 94.773 percent of the shares, respectively voting rights of BioXell S.p.A, Milano. This announcement is made in connection with the recommended public tender offer of Cosmo Pha more
BioXell S.p.A. announced that it has entered into a transaction agreementwith Cosmo Pharmaceuticals S.p.A., under which the parties have agreed on the terms and conditions according to which Cosmo will launch a public tender offer (Offer) for all outstanding shares of BioXell. Pursuant to the term more
BB BIOTECH AG (BB BIOTECH) is a Switzerland based investment company, principally engaged in investing in biotech companies related to oncology, cardiovascular diseases, infectious diseases and autoimmune diseases. The company’s portfolio includes Actelion, Gilead, Celgene, Vertex Pharmaceuticals, G more
Home About us Services Discovery Programs Technologies News&Events Careers News&Events Contact Download Privacy Disclaimer Site map 2005 News News 2010 2009 2008 2007 2006 2005 2004 2003 Events 2010 2009 2008 2007 2006 2005 2004 November 2005 Axxam Opens New Facility at Polaris Scien more
TO BUSINESS AND MEDICAL EDITORS: Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer NEW YORK, Jan. 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metab more
Virdante pharmaceuticals Printable page
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
